Thus, we performed liquid chromatography-mass spectrometry (LC-MS) analysis on fresh A375 (BRAF mutant human melanoma, Low-OXPHOS) and A375-R1 (A375 subclone with acquired resistance to MAPKi and High-OXPHOS) intracranial xenografts to further explore the metabolic features of High- and Low-OXPHOS MBMs.9 As expected, A375-R1 MBMs had significantly higher concentrations of the TCA cycle metabolites malate and fumarate, and lower concentrations of the glycolytic metabolites phosphoenolpyruvate and 3-phosphoglycerate, versus A375 (Figure 3B). Here, BRAF is linked to melanoma.